Helsinki Committee (IRB) Israel: A Complete Guide for MedTech Founders

What is the Helsinki Committee and why is it required?

The Helsinki Committee is the Israeli implementation of an institutional review board (IRB) — a committee that evaluates the ethics, safety, and scientific merit of any proposed clinical trial involving human subjects. The name comes from the Declaration of Helsinki, adopted by the World Medical Association in 1964 and revised multiple times since.

Every Israeli hospital and medical center has its own Helsinki Committee. Any clinical trial, medical device pilot, or research involving patients MUST be approved by the Helsinki Committee at the hospital where the trial will be conducted, BEFORE any patient can be enrolled. Trials conducted without Helsinki approval are illegal under Israeli law (Public Health Regulations, 1980) and void from a regulatory standpoint.

Who needs Helsinki Committee approval?

You need Helsinki approval if any of the following apply: (1) You're running a clinical trial to demonstrate efficacy of a medical device or software. (2) You're collecting patient data (even anonymized) for a research study. (3) You're conducting a clinical pilot to support FDA 510(k) or CE submission. (4) You're testing a MedTech product on patients before market release. (5) You're publishing peer-reviewed research based on patient data.

You may NOT need Helsinki approval if: You're using fully de-identified historical data (retrospective analysis) AND no patient can be re-identified. However, most HMOs (including Leumit) require Helsinki approval even for de-identified data access — this is a policy choice, not a legal requirement, but it's universal practice.

The submission documents

A standard Helsinki submission package includes: (1) **Protocol document** — 50-80 pages describing study objective, design, statistical analysis plan, inclusion/exclusion criteria, risks, benefits, safety monitoring. (2) **Informed Consent Form** — patient-facing document explaining the study in plain language, translated to Hebrew, Arabic, Russian (and English if applicable). (3) **Investigator Brochure** — device safety data, animal study results, regulatory history. (4) **CVs of all investigators** — the principal investigator and co-investigators. (5) **Insurance coverage proof** — professional liability + patient injury coverage. (6) **Sponsor declaration** — financial and regulatory commitments.

Total document package: typically 200-400 pages. Preparing this properly is the single biggest time investment — typically 3-6 weeks of work for a first-time submitter. Experienced regulatory consultants (or WeCcelerate-Leumit) can prepare the package in 1-2 weeks using templated protocols.

Timeline: 2-4 months for standard protocols

From submission to approval: **2-4 months** for a standard protocol. The timeline breakdown: (1) Initial review by Helsinki Committee secretariat: 2-3 weeks. (2) First committee meeting: meets monthly at most hospitals. (3) Revision requests + resubmission: 2-4 weeks. (4) Final approval: 1-2 weeks after resubmission.

Timeline can extend to 6+ months if: (a) The protocol is novel or high-risk, requiring external expert review. (b) The submission is incomplete and requires multiple revision cycles. (c) The committee meets quarterly instead of monthly. WeCcelerate-Leumit partnership typically achieves approval in **6-10 weeks** due to pre-negotiated templates and direct access to Leumit's Helsinki Committee.

Common reasons for rejection or revision

Most rejections or revision requests are procedural, not scientific. Top reasons: (1) **Informed consent not in plain language** — the committee expects 8th-grade reading level, not medical jargon. (2) **Insufficient translation quality** — Arabic and Russian translations by non-native speakers get flagged immediately. (3) **Risk/benefit ratio unclear** — the protocol must demonstrate that expected benefits outweigh risks. (4) **Inclusion/exclusion criteria too vague** — must be quantitative (e.g., "HbA1c > 7.0%" not "poorly controlled diabetes").

Genuine scientific rejection is rare — typically <5% of submissions. The committee's role is to ensure ethics and safety, not to judge scientific novelty. That said, if the protocol is methodologically unsound (e.g., underpowered sample size, no control group where one is needed), the committee will ask for revisions.

Helsinki approval with WeCcelerate-Leumit

The WeCcelerate-Leumit MedTech Accelerator dramatically shortens the Helsinki timeline. Our approach: (1) We provide protocol templates that have passed Helsinki approval multiple times. (2) We have an in-house translator for Hebrew/Arabic/Russian informed consent forms. (3) We have pre-negotiated relationships with Leumit's Helsinki Committee (covering 40+ Leumit clinics). (4) We support you through revisions. Typical timeline: **6-10 weeks** from protocol drafting to committee approval, vs. 12-16 weeks for a first-time submitter going alone.